Is The Proof of an Additional Benefit under amnog in Germany More Difficult for Certain Drugs than for Other Ones?
Abstract
Authors
W Kotowa S Reindl J Mathes T Doyno A Höer
W Kotowa S Reindl J Mathes T Doyno A Höer
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now